Cramer said what makes Pfizer (PFE) attractive is that many of its drugs can be used for "multiple indications," or to treat multiple forms of cancer, which make them more desirable. He said these multiple indications will help bump oncology drug from only 5% of the company's sales to a number much higher.

Biggest pharma

Johnson & Johnson (JNJ) is stalled, so is Pfizer (PFE). Same with Kraft (KFT).

Pfizer (PFE) scares me in the list, adds Guy Adami but there's no denying that Einhorn is the man.

People will always get sick

"The key issue to focus on in the next four months is top-line revenue growth," says David Kostin, Goldman Sachs' chief U.S. strategist. Since peaking at $91 a share in mid-2007, S&P 500 profits have suffered the worst contraction since the Great Depression, falling 53%. During this stretch, companies have cut jobs, slashed fixed costs and amassed considerable operating leverage that can come in handy when revenue grows again. Kostin thinks companies exposed to the faster-growing economies of Brazil, Russia, India and China are better positioned to deliver such growth. To that end, Goldman has flagged a basket of 50 U.S. stocks with the highest percentage of sales to these BRIC countries. The selection includes Sohu.com (ticker: SOHU), Marvell Technology (MRVL), Mylan Laboratories (MYL), Pfizer (PFE), Morgan Stanley (MS) and Yum! Brands (YUM).

think going higher to 25

On Aug. 17's "Lightning Round" segment, Cramer said that Pfizer reminds him of a U.S. savings bond, and he preferred Merck (MRK), Eli Lilly (LLY) and Bristol-Myers (BMY).

industry

Same as above

The pharmaceutical industry seems to be the hardest to pick a winner so the whole industry scares me.

Not sure,but may not be honest.

going noware

dog

no pipeline

anti-stockholder company

boring

Legal problems & Not strongest of Pharm

stock is down

Management. Did not like Wyeth acquisition. Cut dividend I thought was safe.